HS-10380 / Jiangsu Hansoh Pharma - LARVOL DELTA

Hansoh Pharmaceuticals initiates Phase I clinical trial of [14C]HS-10380 for schizophrenia [Google translation] (Sina Corp) - "Data from the Drug Clinical Trial Registration and Information Disclosure Platform indicates that Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh Technology Co., Ltd. have initiated a Phase I clinical trial of [14C]HS-10380 in healthy Chinese participants to investigate its substance balance. The clinical trial registration number is CTR20253108, and the first public disclosure date is August 6, 2025."

Trial status • Schizophrenia

Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia (clinicaltrials.gov) - P1/2 | N=112 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1/2 trial • CNS Disorders • Psychiatry • Schizophrenia • PRL

A Study of HS-10380 in Chinese Participants (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Trial completion date: Jan 2023 ➔ Jul 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia • PRL

A Study of HS-10380 in Chinese Participants (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Psychiatry • Schizophrenia • PRL

A Study of HS-10380 in Chinese Participants (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • CNS Disorders • Psychiatry • Schizophrenia • PRL